- With this agreement, Mi Tres Torres Clinic is positioned as a reference center in Europe in Whole Genome Sequencing for healthy people.
- Both institutions will move forward to realize the biggest and immediate challenge of health care: the exercise of specially predictive, preventive and personalized medicine, focused on the care and promotion of health.
- For more than 3 years, Veritas Genetics commercializes the Whole Genome Sequencing and its interpretation, and was the first company to offer this service to the general public.
- Veritas Intercontinental will contribute to this agreement with its expertise in diagnosis and genetic counselling, Whole Genome Sequencing process, the interpretation of it, as well as support and specific training to the Mi Tres Torres team involved in the Genomic Medicine Unit.
Veritas Intercontinental and the Mi Tres Torres Clinic in Barcelona will create its first Genomic Medicine Unit based on Whole Genome Sequencing. With this agreement, the Mi Tres Torres Clinic is positioned as a reference center in Europe in Whole Genome Sequencing for healthy people, with a Unitthat will be led by Drs. Antonio González and Tomás Torres.
Veritas Intercontinental, subsidiary of Veritas Genetics, “The Genome Company”, will contribute to this agreement with its expertise in genetic counselling and diagnosis, the realization of genome sequencing and interpretation and the ad hoc training of Mi Tres Torres staff.
“The agreement with Veritas Intercontinental will allow us to strengthen our range of services, keeping us at the forefront of healthcare medicine with our first Genomic Medicine Unit in Spain, together with the world leader in Whole Genome Sequencing (WGS) and its interpretation” comments Gaby Masfurroll, CEO of Clínica Mi Tres Torres.
According to Javier de Echevarría, CEO of Veritas Intercontinental, Mi Tres Torres Clinic is a reference center in Europe for the quality of its professionals and the personalized care of its patients “and with this agreement both institutions will move forward to make the biggest and most immediate challenge in healthcare real: Whole Genome Sequencing in the healthy population”.
For Dr. Gonzalez, this Unit of Genomic Medicine will be a key piece in the vision of the clinic, oriented to the promotion and personalized care of health “a field where Whole Genome Sequencing offers a vital roadmap that marks a before and a later in what we now understand as a long and healthy life “.
In this sense, Javier de Echevarría indicates that “we can play the game of life in two ways: blindly, reacting to events, or with the key information provided by the Genome that will allow us to anticipate, so that we can prevent diseases or detect them early, adapt ad hoc and improve their treatment and have a better, longer and healthier life “.
Mi Tres Torres is one of the private health institutions with the most history and prestige in Barcelona. It was founded in 1970 and is located in a residential area of the city. The clinic was acquired by the Masfurroll family at the end of 2014, they have invested more than 10 million euros in a process of total renovation of facilities and technology. The clinic has several buildings in the area that make up the Campus Mi Tres Torres, with outpatient consultations, 50 rooms, 7 operating rooms, a large diagnostic area and more than 10,000 square meters. With Gaby Masfurroll Cortada as CEO, the Clinic has consolidated in this way a transformation into a Boutique Clinic, offering a high level medical service, betting on excellence and exclusive and personalized treatment for the patient. Since the acquisition of the clinic by the Masfurroll family, a large number of prestigious specialists have joined the medical body of the entity.
3 years offering the Genome
For more than 3 years, Veritas Genetics commercializes Whole Genome Sequencing and its interpretation. Its philosophy is to help people to have a longer and healthier life thanks to the information that the Genome offers.
Doctors and scientists from all over the world agree that Whole Genome Sequencing will replace all the other genetic tests, since it offers a powerful resource for a lifetime. From a single sequencing, users will have actionable information that will help them in their family planning, control the risk of disease and live healthier and longer.
Thanks to Veritas Genetics, Genome sequencing is already a “consumer product”. Few years ago, bottlenecks were in the price of sequencing and the ability to manage and interpret large amounts of information. Problems that Veritas has answered to by offering consumers and physicians Whole Genome Sequencing, its interpretation and genetic counseling, information storage services and its management for medical research.
Sobre Veritas Intercontinental
Veritas Intercontinental is the international subsidiary of Veritas Genetics, The Genome Company, which operates in Europe, Latin America, Japan and UAE. Its mission is to promote whole genome and offer people information that empowers them to maximize the quality and duration of their lives and their families, changing the way in which the world conceives genetics.
Veritas was the first company to offer whole genome sequencing and interpretation to consumers and their physicians and leads the field of genetics, expanding the limits of science and technology and reducing the cost of the genome.
Veritas was founded in 2014 by leaders in genomics at the Harvard Medical School and operates worldwide from its offices in the United States, Europe and China. The company has been recognized by MIT Technology Review as one of the 50 Smartest Companies in 2016 and 2017, by Fast Company as one of the most innovative healthcare companies in the world in 2018, and by CNBC as one of the Disruptor 50 companies in 2018 and 2019.